89bio Presents New Analysis of Data from Phase 2 ENTRIGUE
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic
Globe Newswire5-03-2023, 01:31
Zentalis Pharmaceuticals to Participate in Two Upcoming 1-02-2023, 19:08